# T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

> **NCT00683046** · PHASE2 · COMPLETED · sponsor: **University of Chicago** · enrollment: 204 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Lymphoid Leukemia
- Chronic Myelogenous Leukemia
- Malignant Lymphoma
- Hodgkin's Disease
- Chronic Lymphocytic Leukemia
- Myeloproliferative Disorder
- Anemia, Aplastic
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Stem cells
- **DRUG:** Campath

## Key facts

- **NCT ID:** NCT00683046
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2016-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00683046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00683046, "T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00683046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*